Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug maintenance study in moderately to severely active Crohn's disease
2025-521037-86-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 40
01
Overview
Phase 3, randomised, double-blind trial of duvakitug in Crohn's disease (3 arms), sponsored by Sanofi. Planned start Jul 2026; status: authorised.
02
Drugs
duvakitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2025-521037-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521037-86-00.